Arrowhead Pharmaceuticals reported positive Phase 3 top-line results for plozasiran (Redemplo) in severe hypertriglyceridemia, with the data described as meeting primary and key secondary goals across studies and setting up a supplemental NDA filing before year-end. The readouts extend the gene-silencing therapy beyond its existing rare-disease approval into a broader indication. The reported study outcomes include steep triglyceride reductions relative to control and a pooled analysis indicating fewer acute pancreatitis events, a critical clinical risk driven by severe triglyceride elevations. Arrowhead also stated that safety and liver-related biomarkers remained stable, supporting the company’s case for expanded use. The company’s strategy directly pits it against Ionis Pharmaceuticals’ olezarsen (Tryngolza), which recently gained US FDA approval in the same condition, sharpening competitive dynamics in RNA-targeting therapies. For the sector, the update signals how rapidly gene-silencing platforms are being moved from rare-disease footholds into mainstream metabolic indications as Phase 3 packages mature.